Blood test may forecast arthritis severity in kids
NCT ID NCT05534347
First seen Sep 30, 2025 · Last updated Jun 02, 2026 · Updated 28 times
Summary
This study aims to find out if certain proteins in the blood can predict how severe juvenile idiopathic arthritis (JIA) will become in children and teens. Researchers will measure these markers in 300 participants aged 16 and older and track their joint damage and treatments over time. The goal is to better understand the disease and potentially guide more personalized care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Rheumatology Department, Cochin Hospital
RECRUITINGParis, IDF, 75014, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.